Advertisement

Correlation of Early-Phase F-18 Florapronal PET with F-18 FDG PET in Alzheimer’s Disease and Normal Brain

  • Jieun Jeong
  • Young Jin Jeong
  • Kyung Won Park
  • Do-Young KangEmail author
Original Article
  • 2 Downloads

Abstract

Purpose

F-18 florapronol (FPN) is the commercially recognized beta-amyloid positron emission tomography (PET) radiotracer in Korea. This study compared the early F-18 florapronol PET with F-18 fluorodeoxyglucose (FDG) PET between healthy controls (HC) and Alzheimer’s dementia (AD) patients.

Methods

A total of 29 subjects (15 HC and 14 AD subjects) underwent F-18 FPN PET and F-18 FDG PET. F-18 FDG PET image was acquired from 30 to 60 min and F-18 FPN PET for 0 to 10 min. F-18 FPN and F-18 FDG images were spatially normalized with transformation matrices obtained from individual CT images and standardized uptake value ration (SUVR) from cerebellum area, and the global mean was calculated using PMOD 3.6. Pearson’s correlation coefficients between F-18 FDG and early F-18 FPN for predefined cortical brain regions were calculated.

Results

We compared the F-18 FDG and F-18 FPN for SUVR of a specific region in global mean normalization and cerebellum normalization, and most of the correlation coefficient was higher in global mean normalization. In global mean normalization, the correlation coefficient for SUVR of HC was higher than that of AD in all brain regions.

Conclusions

Early F-18 FPN study can be used as a proxy marker for the F-18 FDG PET.

Keywords

Alzheimer’s disease F-18 florapronol Dual time F-18 FDG 

Notes

Acknowledgments

The authors are grateful to PhD Yoon and Ms. Shin for assistance with data processing. This research was supported by the project at Institute of Convergence Bio-Health, DongA University funded by Busan Institute of S&T Evaluation and Planning.

Compliance with Ethical Standards

Conflict of Interest

Jieun Jeong, Yong Jin Jeong, Kyung Won Park, and Do-Young Kang declare that they have no conflict of interest.

Ethical Statement

This study was performed in accordance with the ethical standards laid down in the Helsinki declaration of 1964 and its later revisions.

Informed Consent

Informed consent was obtained from all individual participants included in this prospective study.

References

  1. 1.
    Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–16.CrossRefGoogle Scholar
  2. 2.
    Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–47.CrossRefGoogle Scholar
  3. 3.
    Bullich S, Barthel H, Koglin N, Becker GA, De Santi S, Jovalekic A, et al. Validation of noninvasive tracer kinetic analysis of 18F-florbetaben PET using a dual–time-window acquisition protocol. J Nucl Med. 2018;59:1104–10.CrossRefGoogle Scholar
  4. 4.
    Soyoung Jin, Oh M, Oh SJ, Oh JS, Lee SJ, Chung SJ, et al. Clin Nucl Med. 2017;42:e80–7.CrossRefGoogle Scholar
  5. 5.
    Gur RC, Ragland JD, Reivich M, Greenberg JH, Alavi A, Gur RE. Regional differences in the coupling between resting cerebral blood flow and metabolism may indicate action preparedness as a default state. Cereb Cortex. 2008;19:375–82.CrossRefGoogle Scholar
  6. 6.
    Sokoloff L. Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed Proc. 1981;40:2311–6.Google Scholar
  7. 7.
    Segovia F, Gómez-Río M, et al. Usefulness of dual-point amyloid PET scans in appropriate use criteria: a multicenter study. JAlzheimer’s Dis. 2018;2018(Preprint):1–15.Google Scholar
  8. 8.
    Peretti DE, García DV, Reesink FE, van der Goot T, De Deyn PP, de Jong BM, et al. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer’s disease PET studies. PLoS One. 2019;14:e0211000.CrossRefGoogle Scholar
  9. 9.
    Daerr S, Brendel M, Zach C, Mille E, Schilling D, Zacherl MJ, et al. Evaluation of early-phase 18F-florbetaben PET acquisition in clinical routine cases. NeuroImage: Clinical. 2017;14:77–86.CrossRefGoogle Scholar

Copyright information

© Korean Society of Nuclear Medicine 2019

Authors and Affiliations

  1. 1.Department of Nuclear Medicine, Dong-A University Medical CenterDong-A University College of MedicineBusanSouth Korea
  2. 2.Institute of Convergence Bio-HealthDong-A UniversityBusanSouth Korea
  3. 3.Department of Neurology, Dong-A University Medical CenterDong-A University College of MedicineBusanSouth Korea

Personalised recommendations